Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Roche CD47 antibody start-up gives up-lays off all employees

<< Previous

Bullboard Posts

Next >>

Comment by askretkaon Jul 24, 2023 12:26pm

175 Views

Post# 35554407

RE:RE:RE:RE:RE:Roche CD47 antibody start-up gives up-lays off all employees

I did read somewhere that one company was trying to get a CD47 ab to the target by attaching it to an Oncolytic Virus.

Don't know what Virus they were using though.
Since OVs only infect cancer cells it sremed like a good strategy.

CD47 is on a lot of our cells including RBC and platelets so people with anemia, which is a lot of cancer patients would be at risk, without some sort of targeted specific therapy to attach it to that would only target cancer cells like an OV for instance. Cheers!!!!!!!

<< Previous

Bullboard Posts

Next >>

Options trading in a volatile macro environment